FluGen has been awarded an $11.4 million grant from the United States Department of Defense to conduct a safety and immunogenicity study of the influenza vaccine (M2SR, the company announced…

FluGen, along with Bharat Biotech and virologists at the University of Wisconsin, has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu, the company announced recently….

FluGen announced today it has dosed its first patients in a clinical trial of a novel investigational influenza vaccine called M2SR against multi-season mismatched strains, in Belgium. “If successful, the results from…

FluGen will evaluate its influenza vaccine in a trial of 100 people later this spring, the company announced recently. “Our vaccine contains a live virus that infects you but cannot make…

FluGen announced today it has begun a Phase I clinical trial of its universal influenza vaccine called RedeeFlu. “The initiation of this first-in-man study is an important milestone achieved through…

FluGen announced today that it closed a $12 million Series A financing round. According to a release, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board, Knox LLC and…

After a new type of “bird flu” emerged in China, University of Wisconsin researcher Yoshihiro Kawaoka and his company FluGen began working to make flu vaccines more effective than ever, the university announced…